Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04784533 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
A Phase 2 study, sponsored by Concert Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 317
- Enrollment target
NCT04784533: Completed Phase 2 study, sponsored by Concert Pharmaceuticals.
NCT04784533 is a Phase 2 study that has completed, run by Concert Pharmaceuticals. The registered enrollment target is 317 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (138% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04784533, a Phase 2 study, has completed, sponsored by Concert Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 317 participants
- Enrollment target
Study Summary
This study is designed to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.
Primary Outcome
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20. The percentage of participants achieving LOM criteria (SALT \>20) was compared to the percentage of participants maintaining treatment success (SALT ≤ 20) for each of the following dose reduction conditions. Due to the variable time on study for each participant within Part A Period 2, the primary analysis visit was
Interventions
- DRUG Placebo
- DRUG CTP-543
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2021-02-26 |
| Est. Completion | 2023-05-16 |
| Phase | Phase 2 |
What the finished NCT04784533 record still lists
NCT04784533 is an interventional study that assigns participants to a tested intervention. The registered 317 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (138% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04784533 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04784533 about?
NCT04784533 is a clinical study titled "A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata". This study is designed to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.
What is the current status of trial NCT04784533?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 317 participants. The study started on 2021-02-26. Estimated completion is 2023-05-16.
What interventions are being tested in trial NCT04784533?
The interventions under investigation include: Placebo (DRUG), CTP-543 (DRUG).
Who is sponsoring clinical trial NCT04784533?
This trial is sponsored by Concert Pharmaceuticals, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04784533's enrollment target sits among peer trials
317 155th of 2000 higher than 1,846 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04594642 · 317 participants · Phase 1
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
- NCT04977453 · 317 participants · Phase 1
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- NCT05137054 · 317 participants · Phase 1
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- NCT05382754 · 317 participants · NA
Home Apnea Testing in CHildren Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI